| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accepting risk in the acceleration of drug development for rare cancers
|
Ashley, David
|
|
2015
|
16 |
4 |
p. e190-e194
nvt p.
|
artikel
|
| 2 |
Adjuvant chemotherapy for rectal cancer
|
Bujko, Krzysztof
|
|
2015
|
16 |
4 |
p. e153-
1 p.
|
artikel
|
| 3 |
Adjuvant chemotherapy for rectal cancer
|
You, Kai-yun
|
|
2015
|
16 |
4 |
p. e152-
1 p.
|
artikel
|
| 4 |
Adjuvant chemotherapy for rectal cancer
|
Petrelli, Fausto
|
|
2015
|
16 |
4 |
p. e152-e153
nvt p.
|
artikel
|
| 5 |
Adjuvant chemotherapy for rectal cancer
|
Hofheinz, Ralf-Dieter
|
|
2015
|
16 |
4 |
p. e154-e155
nvt p.
|
artikel
|
| 6 |
Adjuvant chemotherapy for rectal cancer – Authors' reply
|
Breugom, Anne J
|
|
2015
|
16 |
4 |
p. e155-
1 p.
|
artikel
|
| 7 |
A lesson from vorinostat in pleural mesothelioma
|
Garassino, Marina Chiara
|
|
2015
|
16 |
4 |
p. 359-360
2 p.
|
artikel
|
| 8 |
Anti-emetics in paediatric patients receiving chemotherapy
|
Gralla, Richard J
|
|
2015
|
16 |
4 |
p. 351-353
3 p.
|
artikel
|
| 9 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
|
Kang, Hyoung Jin
|
|
2015
|
16 |
4 |
p. 385-394
10 p.
|
artikel
|
| 10 |
Aromatase inhibitors may reduce endometrial cancer risk
|
Brower, Vicki
|
|
2015
|
16 |
4 |
p. e164-
1 p.
|
artikel
|
| 11 |
Bortezomib treatment for patients with mantle-cell lymphoma
|
Tanday, Sanjay
|
|
2015
|
16 |
4 |
p. e162-
1 p.
|
artikel
|
| 12 |
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
|
Hu, Xi-Chun
|
|
2015
|
16 |
4 |
p. 436-446
11 p.
|
artikel
|
| 13 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study
|
Pui, Ching-Hon
|
|
2015
|
16 |
4 |
p. 465-474
10 p.
|
artikel
|
| 14 |
Cooking for patients with cancer: a practical guide
|
Morgan, Jules
|
|
2015
|
16 |
4 |
p. 373-374
2 p.
|
artikel
|
| 15 |
Correction to Lancet Oncol 2014; 15: 856
|
|
|
2015
|
16 |
4 |
p. e158-
1 p.
|
artikel
|
| 16 |
Correction to Lancet Oncol 2015; 16: 60, 61
|
|
|
2015
|
16 |
4 |
p. e158-
1 p.
|
artikel
|
| 17 |
Dangers of direct-to-consumer advertising exposed again
|
The Lancet Oncology,
|
|
2015
|
16 |
4 |
p. 349-
1 p.
|
artikel
|
| 18 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
|
Petrylak, Daniel P
|
|
2015
|
16 |
4 |
p. 417-425
9 p.
|
artikel
|
| 19 |
Failure to improve cancer services in the UK
|
Burki, Talha Khan
|
|
2015
|
16 |
4 |
p. e163-
1 p.
|
artikel
|
| 20 |
First biosimilar drug approved in the USA
|
Burki, Talha Khan
|
|
2015
|
16 |
4 |
p. e161-
1 p.
|
artikel
|
| 21 |
Goserelin reduces chemotherapy-associated ovarian failure
|
Mayor, Susan
|
|
2015
|
16 |
4 |
p. e160-
1 p.
|
artikel
|
| 22 |
Inhibition of IGF-1R in adrenocortical carcinoma
|
Kirschner, Lawrence S
|
|
2015
|
16 |
4 |
p. 356-357
2 p.
|
artikel
|
| 23 |
Late Fragments
|
Lokody, Isabel
|
|
2015
|
16 |
4 |
p. 374-
1 p.
|
artikel
|
| 24 |
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
|
Fassnacht, Martin
|
|
2015
|
16 |
4 |
p. 426-435
10 p.
|
artikel
|
| 25 |
Long-lasting opioids and unintentional overdose
|
Gruber, Karl
|
|
2015
|
16 |
4 |
p. e159-
1 p.
|
artikel
|
| 26 |
Medical Innovation Bill terminated
|
Howe, Rhiannon
|
|
2015
|
16 |
4 |
p. e160-
1 p.
|
artikel
|
| 27 |
Minimal residual disease monitoring: a new era for childhood ALL
|
Schnittger, Susanne
|
|
2015
|
16 |
4 |
p. 362-364
3 p.
|
artikel
|
| 28 |
Mutation patterns in lung cancer never-smokers
|
Gruber, Karl
|
|
2015
|
16 |
4 |
p. e163-
1 p.
|
artikel
|
| 29 |
Nail toxicities induced by systemic anticancer treatments
|
Robert, Caroline
|
|
2015
|
16 |
4 |
p. e181-e189
nvt p.
|
artikel
|
| 30 |
NED (No Evidence of Disease)
|
van Dorn, Aaron
|
|
2015
|
16 |
4 |
p. 372-373
2 p.
|
artikel
|
| 31 |
NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
|
Umeweni, Nwamaka
|
|
2015
|
16 |
4 |
p. 367-368
2 p.
|
artikel
|
| 32 |
NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
|
Lovett, Rosemary
|
|
2015
|
16 |
4 |
p. 369-370
2 p.
|
artikel
|
| 33 |
Nivolumab: another weapon in the growing immunotherapy arsenal
|
Falchook, Gerald
|
|
2015
|
16 |
4 |
p. 350-351
2 p.
|
artikel
|
| 34 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
|
Weber, Jeffrey S
|
|
2015
|
16 |
4 |
p. 375-384
10 p.
|
artikel
|
| 35 |
Nomograms in oncology: more than meets the eye
|
Balachandran, Vinod P
|
|
2015
|
16 |
4 |
p. e173-e180
nvt p.
|
artikel
|
| 36 |
Non-inferiority trials: why oncologists must remain wary
|
Burotto, Mauricio
|
|
2015
|
16 |
4 |
p. 364-366
3 p.
|
artikel
|
| 37 |
Old drugs, new tricks for triple-negative breast cancer
|
Carey, Lisa
|
|
2015
|
16 |
4 |
p. 357-359
3 p.
|
artikel
|
| 38 |
Panitumumab for locally advanced head and neck squamous-cell carcinoma
|
Ishiki, Hiroto
|
|
2015
|
16 |
4 |
p. e156-
1 p.
|
artikel
|
| 39 |
Possible link between hepatitis B infection and gastric cancer
|
Lewis, Ricki
|
|
2015
|
16 |
4 |
p. e159-
1 p.
|
artikel
|
| 40 |
Probiotics and cancer: ready for meal time?
|
Warusavitarne, Janindra
|
|
2015
|
16 |
4 |
p. 371-372
2 p.
|
artikel
|
| 41 |
Radiation in combination with immune-checkpoint inhibitors
|
Mayor, Susan
|
|
2015
|
16 |
4 |
p. e162-
1 p.
|
artikel
|
| 42 |
Radiotherapy dose and fractionation for stage III NSCLC
|
Belderbos, José
|
|
2015
|
16 |
4 |
p. e156-e157
nvt p.
|
artikel
|
| 43 |
Redefining the standard of care in metastatic leiomyosarcoma
|
Noujaim, Jonathan
|
|
2015
|
16 |
4 |
p. 360-362
3 p.
|
artikel
|
| 44 |
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
|
Melichar, Bohuslav
|
|
2015
|
16 |
4 |
p. 395-405
11 p.
|
artikel
|
| 45 |
Sunitinib benefits patients with small-cell lung cancer
|
Tanday, Sanjay
|
|
2015
|
16 |
4 |
p. e164-
1 p.
|
artikel
|
| 46 |
Tackling the cancer epidemic
|
The Lancet Oncology,
|
|
2015
|
16 |
4 |
p. 349-
1 p.
|
artikel
|
| 47 |
The MAINSAIL trial: an expected failure
|
Boccardo, Francesco
|
|
2015
|
16 |
4 |
p. 355-356
2 p.
|
artikel
|
| 48 |
Trabectedin: adding clarification rather than novelty
|
Hohenberger, Peter
|
|
2015
|
16 |
4 |
p. 353-354
2 p.
|
artikel
|
| 49 |
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
|
Pautier, Patricia
|
|
2015
|
16 |
4 |
p. 457-464
8 p.
|
artikel
|
| 50 |
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
|
Kawai, Akira
|
|
2015
|
16 |
4 |
p. 406-416
11 p.
|
artikel
|
| 51 |
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
|
Oser, Matthew G
|
|
2015
|
16 |
4 |
p. e165-e172
nvt p.
|
artikel
|
| 52 |
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
|
Krug, Lee M
|
|
2015
|
16 |
4 |
p. 447-456
10 p.
|
artikel
|
| 53 |
Whole-genome analysis of pancreatic cancer
|
Burki, Talha Khan
|
|
2015
|
16 |
4 |
p. e161-
1 p.
|
artikel
|
Tijdschrift beschrijving